ArticleBMC pregnancy and childbirth2026
The diagnostic and prognostic values of non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Comprehensive antiphospholipid antibody profiling and unsupervised immune phenotyping in fetal growth restriction.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundObstetric antiphospholipid syndrome (OAPS) is a subtype of antiphospholipid syndrome associated with adverse pregnancy outcomes. Non-criteria antiphospholipid antibodies (aPLs) were focused in recent years, but the diagnostic and prognostic values of them in OAPS were rarely explored.
methodsA single-center retrospective study enrolled 283 pregnant women with history of pregnancy loss at an university hospital in sourthwest China. All participants were tested for criteria and non-criteria aPLs, including anticardiolipin antibodies (aCL) IgA, anti-β2 glycoprotein I antibodies (aβ2GPI) IgA, anti-β2 glycoprotein I domain 1 (aβ2GPID1) IgG and anti-phosphatidylserine/ prothrombin (aPS/PT) IgG/IgM. The subsequent pregnancy outcomes were followed up. The prevalence of non-criteria aPLs were compared among patients who classified into OAPS, non-criteria OAPS (NOAPS) and control groups. Receiver operating characteristic (ROC) curve, area under the curve (AUC), sensitivity, specificity and odds ratios (OR) with 95% confidence interval (CI) were calculated to estimate diagnostic and prognostic values of these non-criteria aPLs for OAPS and NOAPS patients.
resultsThe positive rate of aPS/PT IgM was higher in OAPS (44.4%) compared to NOAPS (18.1%) and controls (3.5%) (P < 0.001). aPS/PT IgM presented moderate diagnostic performance in OAPS (AUC = 0.72) but poor performance in NOAPS (AUC = 0.57). Parallel testing of lupus anticoagulant (LAC) and aPS/PT IgM enhanced sensitivity in diagnosing OAPS, and improved accuracy and sensitivity in diagnosing NOAPS. After adjustment, aPS/PT IgM remained a significant predictor of both overall adverse pregnancy outcomes (OR = 3.85, 95% CI: 1.10–13.40, P = 0.03) and early pregnancy loss before 10 weeks (OR = 4.87, 95% CI: 1.03–23.05, P = 0.04) in OAPS patients. However, due to the extremely low positive rates, we did not observe clinical significance of aCL IgA, aβ2GPI IgA, aß2GPID1 IgG and aPS/PT IgG.
conclusionsaPS/PT IgM exhibits diagnostic and prognostic value for OAPS patients. For NOAPS patients, parallel testing of aPS/PT IgM and LAC may improve diagnostic performance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.